Display options
Cite
Díaz-Vesga MC, Zúñiga-Cuevas Ú, Ramírez-Reyes A, et al. Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury. Front Cardiovasc Med. 2021;8:770421doi: 10.3389/fcvm.2021.770421.
Díaz-Vesga, M. C., Zúñiga-Cuevas, �. �., Ramírez-Reyes, A., Herrera-Zelada, N., Palomo, I., Bravo-Sagua, R., & Riquelme, J. A. (2021). Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury. Frontiers in cardiovascular medicine, 8770421. https://doi.org/10.3389/fcvm.2021.770421
Díaz-Vesga, Magda C, et al. "Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury." Frontiers in cardiovascular medicine vol. 8 (2021): 770421. doi: https://doi.org/10.3389/fcvm.2021.770421
Díaz-Vesga MC, Zúñiga-Cuevas Ú, Ramírez-Reyes A, Herrera-Zelada N, Palomo I, Bravo-Sagua R, Riquelme JA. Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury. Front Cardiovasc Med. 2021 Nov 19;8:770421. doi: 10.3389/fcvm.2021.770421. eCollection 2021. PMID: 34869687; PMCID: PMC8639870.
Copy Download .nbib Format: NLM
Share it on

Front Cardiovasc Med. 2021 Nov 19;8:770421. doi: 10.3389/fcvm.2021.770421. eCollection 2021.

Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury.

Frontiers in cardiovascular medicine

Magda C Díaz-Vesga, Úrsula Zúñiga-Cuevas, Andrés Ramírez-Reyes, Nicolas Herrera-Zelada, Iván Palomo, Roberto Bravo-Sagua, Jaime A Riquelme

Affiliations

  1. Programa de Fisiología y Biofísica, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
  2. Grupo de Investigación en Ciencias Básicas y Clínicas de la Salud, Pontificia Universidad Javeriana de Cali, Cali, Colombia.
  3. Advanced Center for Chronic Disease (ACCDiS), Facultad de Ciencias Químicas y Farmacéuticas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
  4. Thrombosis Research Center, Faculty of Health Sciences, Universidad de Talca, Talca, Chile.
  5. Interuniversity Center for Healthy Aging, Chile.
  6. Instituto de Nutrición y Tecnología de los Alimentos (INTA), Universidad de Chile, Santiago, Chile.

PMID: 34869687 PMCID: PMC8639870 DOI: 10.3389/fcvm.2021.770421

Abstract

Despite important advances in the treatment of myocardial infarction that have significantly reduced mortality, there is still an unmet need to limit the infarct size after reperfusion injury in order to prevent the onset and severity of heart failure. Multiple cardioprotective maneuvers, therapeutic targets, peptides and drugs have been developed to effectively protect the myocardium from reperfusion-induced cell death in preclinical studies. Nonetheless, the translation of these therapies from laboratory to clinical contexts has been quite challenging. Comorbidities, comedications or inadequate ischemia/reperfusion experimental models are clearly identified variables that need to be accounted for in order to achieve effective cardioprotection studies. The aging heart is characterized by altered proteostasis, DNA instability, epigenetic changes, among others. A vast number of studies has shown that multiple therapeutic strategies, such as ischemic conditioning phenomena and protective drugs are unable to protect the aged heart from myocardial infarction. In this Mini-Review, we will provide an updated state of the art concerning potential new cardioprotective strategies targeting the aging heart.

Copyright © 2021 Díaz-Vesga, Zúñiga-Cuevas, Ramírez-Reyes, Herrera-Zelada, Palomo, Bravo-Sagua and Riquelme.

Keywords: aging; cardioprotection; ischemia/reperfusion injury; mitochondria; senolytics

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Eur Heart J. 2020 Aug 14;41(31):2974-2982 - PubMed
  2. J Eval Clin Pract. 2019 Oct;25(5):754-760 - PubMed
  3. Nature. 2020 Jul;583(7814):127-132 - PubMed
  4. Cardiology. 2014;128(2):209-19 - PubMed
  5. Sci Rep. 2020 Feb 19;10(1):2896 - PubMed
  6. Nature. 2018 Sep;561(7721):45-56 - PubMed
  7. Cardiovasc Drugs Ther. 2018 Apr;32(2):165-168 - PubMed
  8. Oxid Med Cell Longev. 2020 Aug 3;2020:9219825 - PubMed
  9. Am J Cardiol. 2017 Aug 15;120(4):522-526 - PubMed
  10. Basic Res Cardiol. 2017 Nov 15;113(1):2 - PubMed
  11. Basic Res Cardiol. 2020 Nov 13;115(6):69 - PubMed
  12. Comput Math Methods Med. 2021 Aug 9;2021:6415275 - PubMed
  13. Nat Commun. 2019 Oct 21;10(1):4731 - PubMed
  14. Cell Metab. 2021 Sep 7;33(9):1853-1868.e11 - PubMed
  15. Science. 2016 Oct 28;354(6311):472-477 - PubMed
  16. FASEB Bioadv. 2020 Mar 20;2(5):304-314 - PubMed
  17. Heart. 2018 Mar;104(5):370-376 - PubMed
  18. J Transl Med. 2018 Apr 27;16(1):112 - PubMed
  19. Aging (Albany NY). 2020 Oct 13;12(19):19809-19827 - PubMed
  20. J Cell Mol Med. 2020 Nov;24(21):12272-12284 - PubMed
  21. Eur J Pharmacol. 2018 Aug 15;833:314-319 - PubMed
  22. J Pineal Res. 2018 Aug;65(1):e12490 - PubMed
  23. Circ Res. 2012 Apr 27;110(9):1226-37 - PubMed
  24. Cardiovasc Drugs Ther. 2020 Sep 26;: - PubMed
  25. Cancer Res. 2013 Aug 15;73(16):5253-65 - PubMed
  26. J Cachexia Sarcopenia Muscle. 2017 Jun;8(3):349-369 - PubMed
  27. Cardiovasc Res. 2020 Sep 1;116(11):1835-1849 - PubMed
  28. Basic Res Cardiol. 2018 Aug 17;113(5):39 - PubMed
  29. Mech Ageing Dev. 2018 Mar;170:2-9 - PubMed
  30. J Am Coll Cardiol. 2011 Jan 4;57(1):9-17 - PubMed
  31. Eur Heart J. 2018 Sep 21;39(36):3393-3395 - PubMed
  32. EBioMedicine. 2019 Sep;47:446-456 - PubMed
  33. Mutat Res Rev Mutat Res. 2020 Apr - Jun;784:108309 - PubMed
  34. Nat Commun. 2014 Dec 18;5:5863 - PubMed
  35. Ann N Y Acad Sci. 2000 Jun;908:99-110 - PubMed
  36. Aging Cell. 2016 Oct;15(5):973-7 - PubMed
  37. EBioMedicine. 2019 Feb;40:554-563 - PubMed
  38. Circulation. 2016 Aug 23;134(8):574-5 - PubMed
  39. Antioxid Redox Signal. 2015 May 1;22(13):1146-61 - PubMed
  40. Nat Rev Cardiol. 2018 Apr;15(4):203-214 - PubMed
  41. Oxid Med Cell Longev. 2016;2016:3480637 - PubMed
  42. JACC CardioOncol. 2020 Mar 17;2(1):97-109 - PubMed
  43. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:779-803 - PubMed
  44. Pharmacol Rev. 2014 Oct;66(4):1142-74 - PubMed
  45. Cell Death Dis. 2021 Jul 2;12(7):665 - PubMed
  46. JMIR Res Protoc. 2020 Sep 23;9(9):e19456 - PubMed
  47. Br J Pharmacol. 2020 Dec;177(23):5252-5269 - PubMed
  48. Nat Rev Cardiol. 2020 Dec;17(12):773-789 - PubMed
  49. Best Pract Res Clin Anaesthesiol. 2011 Sep;25(3):305-17 - PubMed
  50. Aging Cell. 2020 Apr;19(4):e13128 - PubMed
  51. FASEB J. 2006 Jul;20(9):1543-5 - PubMed
  52. EBioMedicine. 2018 Oct;36:18-28 - PubMed
  53. Nat Metab. 2019 Nov;1(11):1074-1088 - PubMed
  54. Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6301-10 - PubMed
  55. Basic Res Cardiol. 2018 Jan 15;113(2):9 - PubMed
  56. Thromb Haemost. 2015 Mar;113(3):441-51 - PubMed
  57. Sci Rep. 2018 May 29;8(1):8258 - PubMed
  58. Front Physiol. 2020 Apr 29;11:366 - PubMed
  59. Cardiovasc Res. 2021 Jan 02;: - PubMed
  60. Nat Rev Immunol. 2010 Dec;10(12):826-37 - PubMed
  61. Nat Rev Cardiol. 2017 Nov;14(11):637-653 - PubMed
  62. Aging Cell. 2020 Feb;19(2):e13096 - PubMed
  63. Cell Syst. 2016 Oct 26;3(4):374-384.e4 - PubMed
  64. Cardiology. 2016;133(2):128-33 - PubMed
  65. Lancet. 2019 Oct 19;394(10207):1415-1424 - PubMed
  66. Front Cardiovasc Med. 2019 Apr 02;6:31 - PubMed
  67. J Cardiovasc Pharmacol Ther. 2020 May;25(3):240-250 - PubMed
  68. FASEB J. 2017 Sep;31(9):4153-4167 - PubMed
  69. Oxid Med Cell Longev. 2018 Feb 25;2018:9173436 - PubMed
  70. Cardiovasc Res. 2017 May 1;113(6):564-585 - PubMed
  71. Indian Heart J. 2020 Nov-Dec;72(6):619-622 - PubMed
  72. Aging Cell. 2019 Jun;18(3):e12945 - PubMed
  73. EMBO J. 2019 Mar 1;38(5): - PubMed

Publication Types